Neurology Clinical Trials Market Size, Share & Drivers, 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Neurology Clinical Trials Market Size Analysis

Global Neurology Clinical Trials Market Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Study Design
1. Introduction
  1. Study Design By Value
2. Interventional
  1. By Value
3. Observational
  1. By Value
4. Expanded Access
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Epilepsy
  1. By Value
3. Parkinson's Disease (PD)
  1. By Value
4. Huntington's Disease
  1. By Value
5. Stroke
  1. By Value
6. Traumatic Brain Injury (TBI)
  1. By Value
7. Amyotrophic Lateral Sclerosis (ALS)
  1. By Value
8. Muscle regeneration
  1. By Value
9. Others
  1. By Value

North America Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Study Design
1. Introduction
  1. Study Design By Value
2. Interventional
  1. By Value
3. Observational
  1. By Value
4. Expanded Access
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Epilepsy
  1. By Value
3. Parkinson's Disease (PD)
  1. By Value
4. Huntington's Disease
  1. By Value
5. Stroke
  1. By Value
6. Traumatic Brain Injury (TBI)
  1. By Value
7. Amyotrophic Lateral Sclerosis (ALS)
  1. By Value
8. Muscle regeneration
  1. By Value
9. Others
  1. By Value
U.S.
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
2. By Study Design
  1. Introduction
    1. Study Design By Value
  2. Interventional
    1. By Value
  3. Observational
    1. By Value
  4. Expanded Access
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Epilepsy
    1. By Value
  3. Parkinson's Disease (PD)
    1. By Value
  4. Huntington's Disease
    1. By Value
  5. Stroke
    1. By Value
  6. Traumatic Brain Injury (TBI)
    1. By Value
  7. Amyotrophic Lateral Sclerosis (ALS)
    1. By Value
  8. Muscle regeneration
    1. By Value
  9. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Study Design
1. Introduction
  1. Study Design By Value
2. Interventional
  1. By Value
3. Observational
  1. By Value
4. Expanded Access
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Epilepsy
  1. By Value
3. Parkinson's Disease (PD)
  1. By Value
4. Huntington's Disease
  1. By Value
5. Stroke
  1. By Value
6. Traumatic Brain Injury (TBI)
  1. By Value
7. Amyotrophic Lateral Sclerosis (ALS)
  1. By Value
8. Muscle regeneration
  1. By Value
9. Others
  1. By Value
U.K.
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
2. By Study Design
  1. Introduction
    1. Study Design By Value
  2. Interventional
    1. By Value
  3. Observational
    1. By Value
  4. Expanded Access
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Epilepsy
    1. By Value
  3. Parkinson's Disease (PD)
    1. By Value
  4. Huntington's Disease
    1. By Value
  5. Stroke
    1. By Value
  6. Traumatic Brain Injury (TBI)
    1. By Value
  7. Amyotrophic Lateral Sclerosis (ALS)
    1. By Value
  8. Muscle regeneration
    1. By Value
  9. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Study Design
1. Introduction
  1. Study Design By Value
2. Interventional
  1. By Value
3. Observational
  1. By Value
4. Expanded Access
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Epilepsy
  1. By Value
3. Parkinson's Disease (PD)
  1. By Value
4. Huntington's Disease
  1. By Value
5. Stroke
  1. By Value
6. Traumatic Brain Injury (TBI)
  1. By Value
7. Amyotrophic Lateral Sclerosis (ALS)
  1. By Value
8. Muscle regeneration
  1. By Value
9. Others
  1. By Value
China
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
2. By Study Design
  1. Introduction
    1. Study Design By Value
  2. Interventional
    1. By Value
  3. Observational
    1. By Value
  4. Expanded Access
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Epilepsy
    1. By Value
  3. Parkinson's Disease (PD)
    1. By Value
  4. Huntington's Disease
    1. By Value
  5. Stroke
    1. By Value
  6. Traumatic Brain Injury (TBI)
    1. By Value
  7. Amyotrophic Lateral Sclerosis (ALS)
    1. By Value
  8. Muscle regeneration
    1. By Value
  9. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Study Design
1. Introduction
  1. Study Design By Value
2. Interventional
  1. By Value
3. Observational
  1. By Value
4. Expanded Access
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Epilepsy
  1. By Value
3. Parkinson's Disease (PD)
  1. By Value
4. Huntington's Disease
  1. By Value
5. Stroke
  1. By Value
6. Traumatic Brain Injury (TBI)
  1. By Value
7. Amyotrophic Lateral Sclerosis (ALS)
  1. By Value
8. Muscle regeneration
  1. By Value
9. Others
  1. By Value
UAE
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
2. By Study Design
  1. Introduction
    1. Study Design By Value
  2. Interventional
    1. By Value
  3. Observational
    1. By Value
  4. Expanded Access
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Epilepsy
    1. By Value
  3. Parkinson's Disease (PD)
    1. By Value
  4. Huntington's Disease
    1. By Value
  5. Stroke
    1. By Value
  6. Traumatic Brain Injury (TBI)
    1. By Value
  7. Amyotrophic Lateral Sclerosis (ALS)
    1. By Value
  8. Muscle regeneration
    1. By Value
  9. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Phase
1. Introduction
  1. Phase By Value
2. Phase I
  1. By Value
3. Phase II
  1. By Value
4. Phase III
  1. By Value
5. Phase IV
  1. By Value
By Study Design
1. Introduction
  1. Study Design By Value
2. Interventional
  1. By Value
3. Observational
  1. By Value
4. Expanded Access
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Epilepsy
  1. By Value
3. Parkinson's Disease (PD)
  1. By Value
4. Huntington's Disease
  1. By Value
5. Stroke
  1. By Value
6. Traumatic Brain Injury (TBI)
  1. By Value
7. Amyotrophic Lateral Sclerosis (ALS)
  1. By Value
8. Muscle regeneration
  1. By Value
9. Others
  1. By Value
Brazil
1. By Phase
  1. Introduction
    1. Phase By Value
  2. Phase I
    1. By Value
  3. Phase II
    1. By Value
  4. Phase III
    1. By Value
  5. Phase IV
    1. By Value
2. By Study Design
  1. Introduction
    1. Study Design By Value
  2. Interventional
    1. By Value
  3. Observational
    1. By Value
  4. Expanded Access
    1. By Value
3. By Indication
  1. Introduction
    1. Indication By Value
  2. Epilepsy
    1. By Value
  3. Parkinson's Disease (PD)
    1. By Value
  4. Huntington's Disease
    1. By Value
  5. Stroke
    1. By Value
  6. Traumatic Brain Injury (TBI)
    1. By Value
  7. Amyotrophic Lateral Sclerosis (ALS)
    1. By Value
  8. Muscle regeneration
    1. By Value
  9. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Neurology Clinical Trials Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

IQVIA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Novartis
Covance
Medpace
Charles River Laboratories
SyneousHealth
Icon Plc
GlaxoSmithKline
Aurora healthcare
Biogen

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment